今非昔比:放疗在肾癌中的发展现况  

Reshaping the role of radiotherapy in renal cell carcinoma

作　　者：何立儒[1] 董培[2] 高剑铭[1] 刘洋 周芳坚[2] HE Liru;DONG Pei;GAO Jianming;LIU Yang;ZHOU Fangjian(Department of Radiation Oncology,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou 510060;Department of Urology,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]中山大学肿瘤防治中心放疗科,华南肿瘤学国家重点实验室,肿瘤医学协同创新中心,广东广州510060 [2]中山大学肿瘤防治中心泌尿外科,华南肿瘤学国家重点实验室,肿瘤医学协同创新中心,广东广州510060

出　　处：《现代泌尿外科杂志》2022年第1期1-6,共6页Journal of Modern Urology

摘　　要：肾细胞癌对传统的常规分割放疗不敏感,而立体定向放射治疗(SBRT)能够有效提高肾癌放疗反应率,在局限期和转移期肾癌中的应用愈发广泛。本文通过对SBRT治疗肾癌的基础研究及临床实践资料进行归纳,显示SBRT是局限期不可手术肾癌根治性治疗的替代手段,是转移期肾癌局部治疗的有效手段,与靶向治疗联合安全且可能存在治疗增益,而SBRT的免疫效应以及与免疫治疗的联合将成为未来的探索热点。Renal cell carcinoma(RCC)is resistant to conventionally fractionated radiotherapy.Stereotactic body radiation therapy(SBRT)can increase the response rate to radiotherapy,and has been increasingly used in both localized and metastatic RCC.Herein,we will review the current literature on the underlying mechanism and clinical data on SBRT for RCC.SBRT is not only a treatment option for inoperable localized RCC,but also an effective local treatment modality for metastatic RCC.SBRT combined with targeted therapy is safe,and may bring therapeutic gain.The immune effect of SBRT and its combination with immunotherapy will be the hotspots in the future.

关 键 词：肾细胞癌 立体定向放射治疗 靶向治疗 免疫检查点抑制剂 

分 类 号：R737.11[医药卫生—肿瘤]